ValiRx plc (LON:VAL – Get Free Report) traded up 11.5% on Monday . The company traded as high as GBX 1.84 ($0.02) and last traded at GBX 1.83 ($0.02). 1,677,734 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 1,045,236 shares. The stock had previously closed at GBX 1.64 ($0.02).
ValiRx Price Performance
The company has a debt-to-equity ratio of 0.76, a current ratio of 2.64 and a quick ratio of 1.27. The stock has a 50 day moving average price of GBX 2.32 and a two-hundred day moving average price of GBX 2.87. The firm has a market capitalization of £2.42 million, a price-to-earnings ratio of -82.50 and a beta of 0.59.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
See Also
- Five stocks we like better than ValiRx
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- The Average 401k Balance by Age Explained
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
